RSV

 
How to Talk to Patients About Respiratory Virus Vaccines This Year? The Same Way We Always Do
August 20, 2025

William Schaffner, MD, advises first and foremost to stay away from politics, to acknowledge and normalize patient fear and concern, and to answer quickly and with confidence.

American Academy of Pediatrics Counters CDC with Updated Childhood Immunization Schedule
August 20, 2025

In its updated guidelines, the AAP recommends that all children aged 6 to 23 months be vaccinated against COVID-19, citing the population's high risk for severe infection.

9 Drugs Approved for Primary Care: Q2 2025
July 11, 2025

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

Reconstituted ACIP Votes Yes on Clesrovimab for Infants and Flu Shot For All, But Thimerosal Has Got to Go
June 27, 2025

The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.

ACIP Agenda for First Meeting Since Committee Was Replaced by RKF Jr Raises Questions for What's On It and What's Not
June 25, 2025

The now 7-member ACIP will discuss dated issues including thimerosal in flu vaccine and MMR-related febrile seizures but not vaccines against cervical cancer and pneumonia.

RSV Vaccine Uptake Low Among Eligible Populations, Large-Scale Analysis Finds
April 09, 2025

AAAAI 2025: RSV vaccine and immunoprophylaxis uptake remained low in 2024 across infants, pregnant individuals, and older adults.

Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
February 14, 2025

Your daily dose of the clinical news you may have missed.

COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data
February 03, 2025

Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.

Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
January 30, 2025

The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.

Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy
October 29, 2024

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.